Adicet Bio
About
Adicet Bio is a clinical-stage biotechnology company focused on discovering and developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Their proprietary platform engineers these cells with chimeric antigen receptors (CARs) to provide durable activity in patients. The company's lead product candidate, prulacabtagene leucel (prula-cel), is being developed for autoimmune indications and has received Fast Track Designation from the FDA for certain conditions.
Key facts
At-a-glance profile data
- Website
- adicetbio.com
- Headquarters
- Boston, United States
- Founded
- 2014
- Total funding
- $389M (Registered Direct Offering)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 7 Oct 2025 | Registered Direct Offering | $80M | - |
| 25 Jan 2024 | Follow-on Offering | $98M | - |
| 2 Oct 2020 | Series B | $80M | - |
| 2 Oct 2019 | Series B | $80M | - |
| 27 Jan 2016 | Series A | $51M | OrbiMed |
Tech stack
Detected on adicetbio.com, last scanned 19 Sept 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- Hosting
- AWS
- Email provider
- Mimecast
- Cookie consent
- OneTrust
Add first review
Frequently asked
How much funding has Adicet Bio raised?
Adicet Bio has raised a total of $389M in funding. The most recent round on record is Registered Direct Offering.